Multi-targetable chalcone analogs to treat deadly Alzheimer’s disease: Current view and upcoming advice
- 1 October 2018
- journal article
- research article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 80, 86-93
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (21772150)
- Wuhan University of Technology
This publication has 70 references indexed in Scilit:
- Bioinorganic Chemistry of Alzheimer’s DiseaseChemical Reviews, 2012
- Tacrine-mefenamic acid hybrids for inhibition of acetylcholinesteraseMedChemComm, 2011
- The role of chalcones in suppression of NF-κB-mediated inflammation and cancerInternational Immunopharmacology, 2011
- Synthesis and biological evaluation of indole-chalcone derivatives as β-amyloid imaging probeBioorganic & Medicinal Chemistry Letters, 2011
- Antibacterial and Anti-inflammatory Activities of 4-Hydroxycordoin: Potential Therapeutic BenefitsJournal of Natural Products, 2010
- Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer diseaseAlzheimer's Research & Therapy, 2009
- The modulation of metal bio‐availability as a therapeutic strategy for the treatment of Alzheimer's diseaseThe FEBS Journal, 2007
- The significance of the cholinergic system in the brain during aging and in Alzheimer’s diseaseJournal of Neural Transmission, 2006
- Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefitJournal of Neural Transmission, 2002
- The biosynthesis of C5–C25 terpenoid compoundsNatural Product Reports, 2002